ClinicalTrials.gg
RecruitingNCT06433401Updated Jan 31, 2025

The Effect of Structured Transition Care Model Applied to Adolescents With Congenital Heart Disease

An interventional study of Transitional care training with brochures, posters and slide training materials in Congenital Heart Disease in Adolescence, sponsored by Ankara Yildirim Beyazıt University. Recruiting at 2 sites in Turkey. Open to participants aged 16 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Ankara Yildirim Beyazıt University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
16 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Heart Defects, Congenital with a site in Turkey — 11 open to participants now, 12 under way, none of them phase 3. Heart Defects, Congenital · Turkey.

Planned enrollment
5th of 18
70 · median 51
Started
2024
with 2 others
No phase
17 of 32
8 open now
Primary completion
2025-01
later than 2 of 11 live
Registered
23rd of 32
by date
Lead sponsor
1 of 32
Ankara Yildirim Beyazıt University

Among the 32 studies in Heart Defects, Congenital with a site in Turkey, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 17 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 23rd registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

11 of the 32 studies in Heart Defects, Congenital with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 16 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Heart Defects, Congenital with a site in Turkey, or all of them as a file.
02

Study summary

Congenital heart disease is one of the most common congenital defects with a high mortality and morbidity rate. Children with congenital heart disease step from pediatric care to adult care during adolescence. This situation has brought up transitional care, which is defined as "the purposeful and planned movement of adolescents and young adults with chronic physical and medical conditions from pediatric to adult-oriented health systems". Since adolescents with congenital heart disease are at high risk for complications in adulthood, it is very important to raise awareness, increase the level of readiness for adult care and gain self-management skills during the transition phase. This study was planned as a randomized controlled experimental study to evaluate the effect of the developmental transition care model applied to adolescents with congenital heart disease during the transition from pediatric care to adult care on the transition readiness level, self-management skills and care satisfaction of adolescents.

Studies have shown that both adolescents with congenital heart disease and their caregivers need professional support, appropriate transition education and care before transition to adult care in order to increase adaptation to adult care, to gain self-management skills and to reduce their concerns. Studies in which adolescents are followed up after transition to adult care show that when the transition process is not successfully completed, there is excessive time between the last pediatric control and the first adult control or there are losses in further follow-up. Although there are studies in our country in which transition care is applied, this study is planned because there is no intervention study in which developmental transition care model is applied to adolescents with congenital heart disease. It is thought that this study will increase the transition readiness levels, self-management skills and care satisfaction of adolescents with congenital heart disease and guide the nurses working with them.

Read the detailed description

Congenital heart disease is one of the most common congenital defects with high mortality and morbidity rates. The American Heart Association reports that at least eight out of every 1000 babies born are born with heart disease. In Turkey, an average of 11,000-17,000 babies are born with congenital heart disease each year. Congenital heart diseases are a very large group of diseases and the level and prognosis of defects in this group vary. While severe defects result in neonatal and infant mortality, almost all children with mild defects survive. With the adolescent period, children step from pediatric care to adult care. While the transition to adulthood causes psychological and social changes for a healthy adolescent and his/her family, the need for additional care for adolescents with chronic diseases and the change in access to health services make the transition period even more challenging. This situation has brought transition care, defined as "the purposeful and planned movement of adolescents and young adults with chronic physical and medical conditions from pediatric health systems to adult-oriented health systems" to the agenda. Since adolescents with congenital heart disease are at high risk for complications in adulthood, raising awareness of the need for regular medical follow-up and preparing them for changes in the health care environment are very important for a successful transition.

The aim of transitional care is to maintain the control and well-being of the disease in adulthood and maximize its potential by providing the quality care practices needed by the adolescent without interruption. Studies have shown that both adolescents with congenital heart disease and their caregivers need professional support, appropriate transition education and care before transition to adult care in order to increase their adaptation to adult care, gain self-management skills and reduce their concerns. The American Academy of Pediatrics (APA) recommends that the transition process should begin with transition planning between the ages of 12-14. However, since physiological and psychological development and needs are not related to the chronological age of the individual, the essence of timing in the transition process is flexibility. The timing of transition varies depending on many individual and environmental variables such as age, gender, physical and psychological maturation, current medical condition, compliance and adherence to treatment, readiness of the adolescent for transition, finding an appropriate adult care provider, and insurance policies. In studies in which adolescents with congenital heart disease were followed up after transition to adult care, when the transition process was not successfully completed, there was a gap between the last pediatric control and the first adult control. In conclusion, there is no intervention study in our country in which the developmental transition care model was applied to adolescents with congenital heart disease and the results were evaluated. In addition, based on clinical experiences and observations, it was determined that adolescents and their parents had difficulties in the transition from pediatric care to adult care and this negatively affected self-management related to the disease. The aim of this study was to evaluate the effect of the developmental transition care model applied to adolescents with congenital heart disease during the transition from pediatric care to adult care on the transition readiness level, self-management skills and care satisfaction of adolescents.

03

Conditions studied

  • Congenital Heart Disease in Adolescence

Keywords

  • Congenital heart disease
  • Adolescent
  • Transition care
  • Nurses
04

Who can participate

Ages eligible
16 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily agree to participate in the research
  • To be between the ages of 16-20,
  • Having a diagnosis of congenital heart disease,
  • Being followed up with a diagnosis of congenital heart disease for at least one year in the polyclinics where the study was conducted,
  • To be able to communicate in Turkish,
  • Not having any mental deficiency that may prevent communication

Exclusion criteria

Exclusion Criteria:

  • Refusing to participate in the research,
  • Not being able to communicate in Turkish,
  • Not showing up regularly for follow-ups,
  • Having any mental disability that may prevent communication
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Transition care group

    The transitional care group is a group that will receive a transitional care training consisting of a total of 3 modules in which the content is arranged for individualized needs with expert opinion from 10 faculty members working in the field of Child Health and Diseases Nursing.The education sessions will be conducted every months in sessions of approximately 35-40 minutes face-to-face in the training room allocated to the individual researcher.

    Behavioral: Transitional care training with brochures, posters and slide training materials

  • No intervention
    Control group

    The control group is the group receiving routine care that continues the normal follow-up of the clinic without any intervention. However, in terms of compliance with ethical principles, the same training will be given to them upon their request after the research is completely completed.

Interventions

  • BehavioralTransitional care training with brochures, posters and slide training materials

    Education at 1 and 2 months after the first interview

06

What researchers measure

Primary outcomes

  1. Transition Readiness Assessment Scale

    It addresses the readiness of adolescents/young adults with chronic diseases to transition from pediatric care to adult care with the sub-dimensions of management of treatment, management of appointments, monitoring of health status, communication with health personnel and management of daily activities. The Cronbach alpha internal consistency coefficient of the Turkish scale was .88. The readiness for transition assessment scale is a 5-point Likert-type self-assessment scale to assess the skills and behaviors required for disease management in five sub-dimensions. Each item is evaluated between 1 point (no, I do not know how to do it) and 5 points (yes, I can do it when I need to). Adolescents score a minimum of 20 and a maximum of 100 points. The higher the score obtained from the scale, the higher the level of readiness of the adolescent to transition from pediatric care to adult care.

    Time frame: at certain intervals for 1 year

Secondary outcomes

  1. Data Collection Form on Sociodemographic and Medical Characteristics

    This form was prepared by the researchers as a result of the literature review and will be used to obtain information on the age, gender, contact information, information on parents interested in health checks, initial diagnosis characteristics (date of diagnosis and complaints of hospital admission), degree of congenital heart disease, information on regularly used medication, body mass index, physical activity status, nutritional status, vital signs, cardiac examination and imaging information of adolescents.

    Time frame: at certain intervals for 1 year

  2. Chronic Disease Self-Management Scale

    This scale to determine the disease management skills of individuals with chronic diseases The scale consists of 21 items and 4 sub-dimensions. These sub-dimensions are self-stigmatization, coping with stigmatization, health care effectiveness and treatment compliance. It was stated that the scale is suitable for use in all individuals with chronic diseases. The scale score is calculated by arithmetic mean. Each item in the scale is scored between 1 and 5. Scores obtained from the scale indicate that self-management increases as it approaches 5, and self-management decreases as it decreases towards 1.

    Time frame: at certain intervals for 1 year

  3. Transitional Care Satisfaction Rating Scale

    The scale allows adolescents with chronic diseases to self-assess the care they receive and to determine their expectations; it is a scale that addresses the care provided with the dimensions of "Management of the Physical Environment (PME)", "Health Personnel Characteristics (HCP)" and "Care Process (CP)". The form of the scale used for adolescents consists of two separate questionnaires (ideal care/existing care) with 21 questions in which the adolescent's expected care and current care are evaluated. The scale forms are 7-point Likert-type with 1=strongly disagree and 7=strongly agree. Participants are asked to rate their current care based on the best care they expect for themselves. Scoring is based on the difference between the individual's expectations and what they actually perceive.

    Time frame: at certain intervals for 1 year

07

Study locations

1 of 2 sites recruiting
  • Republic of Turkey Ministry of Health Ankara Etlik City Hospital
    Ankara, Ankara Yenimahalle 06170, Turkey
    Not yet recruiting
  • Republic of Turkey Ministry of Health Ankara Etlik City Hospital
    Ankara, Turkey
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2025, 5 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 5 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
May 29, 2024
StartActual
Aug 29, 2024
Primary completionEst.
Jan 30, 2025
CompletionEst.
Mar 30, 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06433401
Responsible party
tutkukırçı (Principal Investigator, Ankara Yildirim Beyazıt University) — Principal investigator
First posted
May 29, 2024
Start date
Aug 29, 2024
Primary completion
Jan 30, 2025 (estimated)
Completion
Mar 30, 2025 (estimated)
Last update
Jan 31, 2025

Study contacts

Tutku KIRÇI TEMİZ, PhD s.
Contact
tutkukrc29095@gmail.com
+905064278982
Utku ARMAN ÖRÜN, Prof.Dr.
Contact
utkuarman.orun@sbu.edu.tr
+905322933072
Tutku KIRÇI TEMİZ, PhD s.
principal investigator · Ankara Yildirim Beyazıt University
Evrim KIZILER, Asst.Prof.
study director · Ankara Yildirim Beyazıt University
Utku ARMAN ÖRÜN, Prof.Dr.
study director · Republic of Turkey Ministry of Health Ankara Etlik City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion